Intellipharmaceutics International Inc. (IPCI)

[AngeloFoca]

Special to The Life Sciences Report (5/11/16)

The key for us over the next three months is to file the NDA for Rexista™. We anticipate an FDA PDUFA action date within a six-month period, or by early 2017. We believe achieving this important milestone would open up other doors for the Intellipharmaceutics, particularly when it comes to securing credible partnering opportunities leading to the commercialization of Rexista™ on terms that are favorable or acceptable to us.

You would not say "on terms that are favorable or acceptable to us" unless you had already had offers that were NOT favorable or acceptable to them.